BG104162A - Фармацевтичен състав, активен в намаляване продукцията на мср-1 протеин - Google Patents

Фармацевтичен състав, активен в намаляване продукцията на мср-1 протеин

Info

Publication number
BG104162A
BG104162A BG104162A BG10416200A BG104162A BG 104162 A BG104162 A BG 104162A BG 104162 A BG104162 A BG 104162A BG 10416200 A BG10416200 A BG 10416200A BG 104162 A BG104162 A BG 104162A
Authority
BG
Bulgaria
Prior art keywords
mcp
pharmaceutical composition
reduction
composition active
protein production
Prior art date
Application number
BG104162A
Other languages
English (en)
Inventor
Angelo Guglielmotti
Claudio Milanese
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Publication of BG104162A publication Critical patent/BG104162A/bg

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретението се отнася до използване на съединение (бендазак) с формула@@и до негови соли с фармацевтично приемливи органични или неорганични основиза получаване на фармацевтичен състав, активен при лечението на нарушения, характеризиращи се с продукцията на МСР-1 протеин.
BG104162A 1997-07-28 2000-02-17 Фармацевтичен състав, активен в намаляване продукцията на мср-1 протеин BG104162A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI001788A IT1293794B1 (it) 1997-07-28 1997-07-28 Farmaco attivo nel ridurre la produzione di proteina mcp-1
PCT/EP1998/004925 WO1999004791A1 (en) 1997-07-28 1998-07-22 A pharmaceutical composition active in reducing production of mcp-1 protein

Publications (1)

Publication Number Publication Date
BG104162A true BG104162A (bg) 2000-12-29

Family

ID=11377641

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104162A BG104162A (bg) 1997-07-28 2000-02-17 Фармацевтичен състав, активен в намаляване продукцията на мср-1 протеин

Country Status (15)

Country Link
US (1) US6191158B1 (bg)
EP (1) EP0999836A1 (bg)
JP (1) JP2001510802A (bg)
KR (1) KR20010022333A (bg)
CN (1) CN1265592A (bg)
AU (1) AU9160298A (bg)
BG (1) BG104162A (bg)
CA (1) CA2298507A1 (bg)
EA (1) EA200000168A1 (bg)
HU (1) HUP0004936A3 (bg)
IL (1) IL134050A0 (bg)
IT (1) IT1293794B1 (bg)
SK (1) SK1332000A3 (bg)
TR (1) TR200000244T2 (bg)
WO (1) WO1999004791A1 (bg)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970194A (en) * 1975-01-08 1976-07-20 Philip Morris Incorporated Razor blade cartridge and display article
IT1147079B (it) * 1980-05-30 1986-11-19 Sigma Tau Ind Farmacuetiche Ri Esteri di alcossi-acil derivati della carnitina procedimento per la loro preparatione e composizioni farmaceutiche che li contengono
IT1131779B (it) * 1980-07-29 1986-06-25 Acraf Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione
IT1189052B (it) * 1981-11-27 1988-01-28 Acraf Trattamento della cataratta
IT1197805B (it) * 1986-08-01 1988-12-06 Acraf Metodo per il tratamento di lenti a contatto

Also Published As

Publication number Publication date
SK1332000A3 (en) 2000-12-11
EA200000168A1 (ru) 2000-08-28
KR20010022333A (ko) 2001-03-15
TR200000244T2 (tr) 2000-09-21
EP0999836A1 (en) 2000-05-17
WO1999004791A1 (en) 1999-02-04
HUP0004936A2 (hu) 2001-11-28
ITMI971788A1 (it) 1999-01-28
CN1265592A (zh) 2000-09-06
JP2001510802A (ja) 2001-08-07
CA2298507A1 (en) 1999-02-04
IT1293794B1 (it) 1999-03-10
AU9160298A (en) 1999-02-16
US6191158B1 (en) 2001-02-20
HUP0004936A3 (en) 2002-01-28
IL134050A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
MY115662A (en) Novel compounds with analgesic effect
WO2000046199A3 (en) Indole derivatives as anti-inflammation agents
AP2002002637A0 (en) Novel piperazine
JO3404B1 (ar) تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين
BG104877A (bg) N-заместени аминотетралини като лиганди за невропептиден y y5 рецептор, използвани при лечение на напълняване и други смущения
MY130145A (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
CA2274074A1 (en) Novel compounds with analgesic effect
NZ514711A (en) Compounds useful as anti-inflammatory agents
BG106586A (bg) Пиразолопиримидини като терапевтични средства
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MY132705A (en) Novel compounds with analgesic effect
CA2289717A1 (en) Novel therapy for constipation
MY113733A (en) Salts of an anti-migraine indole derivative
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
CA2129995A1 (en) Piperidinyl thiacyclic derivatives
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
MY113062A (en) Amide derivatives and their therapeutic use
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
GEP19991869B (en) Amino Acid Derivatives of Substituted Quinoxaline 2,3-Dione Derivatives as Glutamate Receptor Antagonists
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents